Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhino 25 Platinum is an **unapproved sexual enhancement product** marketed as a dietary supplement rather than a legitimate pharmaceutical developed through a regulated drug-development program. Public safety findings indicate that it contains **undeclared sildenafil**, a small-molecule **phosphodiesterase type-5 inhibitor** that increases cyclic guanosine monophosphate signaling and promotes smooth-muscle relaxation in the corpus cavernosum to facilitate erection. The product has been the subject of FDA warnings because the hidden active ingredient creates risks typical of sildenafil exposure, including potentially dangerous hypotension, especially with nitrates, as well as headache, chest pain, and priapism. It is not an approved prescription drug, has no legitimate disclosed developer, and is sold illegally through channels such as convenience stores, gas stations, and online sellers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rhino 25 Platinum.